Learning outcomes
By the end of this lesson you should be able to: describe the natural history of the coronary atherosclerotic plaque and the event that converts a stable plaque into an acute occlusion; differentiate stable angina from unstable angina and the acute coronary syndromes using the history, the ECG and the troponin; interpret the distribution of ST changes against the coronary territories; state the immediate treatment of an acute coronary syndrome and the reperfusion strategy for an ST-elevation infarction; and list the components of secondary prevention.
Prerequisites
PATH 201 (atherosclerosis, thrombosis and infarction), PHYS 101 (the coronary circulation, myocardial oxygen supply and demand), MED 301 lesson 5 (the ECG, including the ST segment), and lesson 6 (ABCDE).
The big idea
The single unifying idea is that the myocardium extracts nearly as much oxygen from the blood it receives as is possible at rest, so any increase in demand must be met by an increase in flow. A normal coronary artery can increase flow roughly five-fold; a narrowed one cannot. At rest the narrowed artery may still suffice, which is why the patient is well until effort raises demand, and why the pain stops on rest. Ischaemia is therefore a demand-supply mismatch, and everything the disease does follows from that arithmetic.
Atherosclerosis: from fatty streak to rupture
| Stage | What happens | Clinical consequence |
|---|---|---|
| Endothelial injury | Hypertension, smoking, hyperglycaemia and hyperlipidaemia damage the endothelium and increase its permeability | Silent; this is the modifiable stage and the reason for risk-factor treatment |
| Fatty streak | Low-density lipoproteins enter the intima, oxidise, and are taken up by macrophages, which become foam cells | Silent, and present in the autopsies of young adults |
| Fibrous plaque | Smooth muscle cells migrate and lay down a collagen cap over a lipid-rich core | Luminal narrowing, so exertional angina appears when the stenosis exceeds about 70 percent |
| Plaque rupture or erosion | The thin cap tears, exposing collagen and tissue factor, so platelets aggregate and the coagulation cascade activates to form a thrombus | The acute coronary syndrome: an occlusive thrombus produces infarction, a non-occlusive one produces unstable angina or a non-ST-elevation infarction |
| Healing and remodelling | Organisation of the thrombus and further cap formation | A new stable stenosis, progressive symptoms and heart failure |
The clinically important point is that the dangerous plaque is not necessarily the most narrow one. A lipid-rich plaque with a thin cap and active inflammation is more likely to rupture than a small, calcified, heavily narrowed lesion, which is why a patient can have a first myocardial infarction with no history of angina, and why risk-factor treatment is aimed at the plaque rather than at the stenosis.
NoteAn atheromatous plaque is said to be vulnerable when its lipid core is large, its cap is thin and inflamed, and it is composed of foam cells with few smooth muscle cells. That composition — not the diameter of the lumen — is what determines rupture risk.
The clinical syndromes
| Syndrome | History | ECG | Troponin |
|---|---|---|---|
| Stable angina | Predictable exertional central chest tightness, relieved by rest or by sublingual nitrate within minutes, unchanged for months | Normal at rest, or unchanged Q waves; ST depression may appear during pain | Normal |
| Unstable angina | Angina at rest or with minimal exertion, new-onset severe angina, angina that is more frequent, more severe or longer than before (crescendo) | ST depression or T wave inversion, or normal; no ST elevation | Normal |
| Non-ST-elevation myocardial infarction (NSTEMI) | Pain at rest lasting more than 20 minutes with the same character as stable angina, often with sweating, nausea and vomiting | ST depression or transient elevation, deep T inversion, or non-specific; absence of ST elevation | Raised, with a rise and fall pattern |
| ST-elevation myocardial infarction (STEMI) | Severe, sustained, crushing central chest pain with sweating, nausea, vomiting and a sense of impending death, unrelieved by nitrate | Persistent ST elevation of at least 1 millimetre in two contiguous limb leads or 2 millimetres in two contiguous chest leads, or a new left bundle branch block | Raised, with a rise and fall pattern |
Watch outA patient with crescendo pain, pain at rest, or pain lasting more than 20 minutes has an acute coronary syndrome until proven otherwise, whatever the ECG shows. A normal ECG does not exclude an evolving infarction, which is why the troponin and the serial ECG are taken.
The ECG and the coronary territories
| Leads | Wall supplied | Artery | Signs of infarction |
|---|---|---|---|
| II, III and aVF | Inferior wall of the left ventricle | Right coronary artery in most people, the circumflex in others | ST elevation in those leads; reciprocal ST depression in I and aVL; also check the right-sided leads for a right ventricular infarction, because nitrates are dangerous in that setting |
| V1 to V4 | Anterior wall and septum | Left anterior descending artery | ST elevation, often with Q waves; the territory with the largest muscle mass and the highest mortality |
| V5, V6, I and aVL | Lateral wall | Left anterior descending or the circumflex | ST elevation in the lateral leads; may accompany an inferior or anterior infarction |
| V1 to V3 (posterior) | Posterior wall | Right coronary artery or circumflex | ST depression with tall R waves in V1 to V3, which is reciprocal to posterior ST elevation — recorded by adding posterior leads V7 to V9 |
The ST segment should be read against the T wave and the Q wave together. Transmural infarction produces Q waves that persist for life, because the necrosed segment cannot depolarise; subendocardial ischaemia produces ST depression without Q waves. The distinction explains the vocabulary of the syndromes and is directly visible in the tracing.
Diagnosis
| Element | Standard | Note |
|---|---|---|
| Cardiac troponin I or T | A high-sensitivity assay at presentation and repeated at 3 hours; a rise and fall pattern identifies myocardial necrosis | Troponin is a marker of necrosis, not of ischaemia: it is also raised in pulmonary embolism, myocarditis, sepsis, renal failure and heart failure |
| Electrocardiogram | Taken within 10 minutes of first contact, and repeated when the pain changes or an infarct is suspected | Look specifically for ST elevation, new left bundle branch block, ST depression and reciprocal change |
| Chest radiograph | Widened mediastinum, pulmonary oedema, cardiomegaly | Excludes dissection, pneumonia and pneumothorax; the widened mediastinum changes the whole management |
| Other investigations | Full blood count, renal function, electrolytes, glucose, lipids, echocardiography within the admission, coronary angiography | Echocardiography shows the regional wall motion abnormality and any mechanical complication; angiography is both diagnostic and therapeutic |
Immediate treatment of the acute coronary syndrome
| Drug | Action | Cautions |
|---|---|---|
| Aspirin 300 milligrams chewed | Given immediately to every patient with a suspected acute coronary syndrome unless allergic | The single most beneficial and cheapest intervention; the dose is then continued at 75 to 100 milligrams daily |
| P2Y12 inhibitor (ticagrelor or clopidogrel) | A second antiplatelet agent for dual antiplatelet therapy, continued for 12 months after an acute syndrome | Ticagrelor is more effective but causes dyspnoea and is twice daily; bleeding risk with both; avoid in the presence of intracerebral disease |
| Anticoagulant (fondaparinux or unfractionated heparin) | Antithrombin therapy during the acute phase, particularly when an invasive strategy is planned | Dose-adjusted to renal function; monitor if heparin is used |
| Sublingual or intravenous nitrate | Relieves ischaemic pain and reduces preload | Contraindicated with a systolic below 90, with right ventricular infarction, or with recent phosphodiesterase inhibitor use |
| Oxygen | Reserved for hypoxaemia, breathlessness or heart failure | Routine high-flow oxygen in a patient with a normal saturation provides no benefit and may be harmful |
| Beta-blocker | Started orally within 24 hours when the patient is haemodynamically stable | Avoid in heart failure, bradycardia, asthma or shock; reduces mortality after infarction |
| High-intensity statin | Started immediately and continued lifelong | An anti-inflammatory and plaque-stabilising action as well as lipid lowering |
Watch outMorphine is not routine in the acute coronary syndrome: it delays the absorption of antiplatelet drugs and is associated with worse outcomes, so it is used only for pain that resists nitrates and when no other option exists.
Reperfusion
| Situation | Strategy | Target time |
|---|---|---|
| ST-elevation infarction with pain of less than 12 hours | Primary percutaneous coronary intervention with stenting | Balloon or device time within 120 minutes of the diagnosis, or within 60 minutes when the patient arrives directly at a centre that performs the procedure |
| ST-elevation infarction where percutaneous intervention cannot be delivered in time | Fibrinolytic (thrombolytic) therapy, ideally within 12 hours of symptom onset and pre-hospital if possible | Door to needle within 30 minutes, with rescue percutaneous intervention if the trace does not settle |
| Non-ST-elevation acute coronary syndrome at high risk | Invasive coronary angiography within 24 hours for a raised troponin, dynamic ST change, haemodynamic instability or a high risk score | Urgent (beats the window for serial troponins) for very high risk; within 72 hours for the remainder |
| Stable angina for revascularisation assessment | Elective angiography for symptoms refractory to therapy, for a large ischaemic burden on functional testing, or for a high risk of an event | After risk stratification, and after the introduction of medical therapy |
Percutaneous intervention opens the artery mechanically and is superior to thrombolysis when it can be delivered in time, because the risk of intracerebral haemorrhage is avoided and the stenosis is stented. Where a patient presents to a hospital that cannot deliver it, the choice is between thrombolysis and transfer, and the decision is arithmetic: if the door-to-device estimate exceeds 120 minutes, thrombolyse. Reperfusion arrhythmias — accelerated idioventricular rhythm, bradycardia in an inferior infarction, and ventricular tachycardia — are common in the first hours and are treated only when they compromise the circulation.
NoteTime is the currency of reperfusion: the proportion of myocardium salvaged falls with every minute of occlusion, so the diagnosis, the ECG and the reperfusion decision are made in parallel rather than in sequence.
Secondary prevention
| Component | Specifics | Purpose |
|---|---|---|
| Antiplatelet therapy | Aspirin lifelong; a second antiplatelet agent for 12 months after an acute syndrome | Reduces recurrent infarction and stent thrombosis |
| Lipid lowering | High-intensity statin (atorvastatin 80 milligrams or equivalent), with an ezetimibe or a PCSK9 inhibitor added if the target is not met | Lowers low-density lipoprotein, stabilises plaque, and reduces events by about a quarter |
| Angiotensin blockade | An ACE inhibitor, particularly after an anterior infarction or with reduced ejection fraction or diabetes | Reduces remodelling, heart failure and mortality |
| Beta-blocker | Continued long term after infarction or in angina | Reduces demand, arrhythmia and mortality |
| Risk factor control | Blood pressure below 130/80 where tolerated, glycaemic control, complete smoking cessation, weight, activity | Slows the disease in every territory, not only the coronary one |
| Cardiac rehabilitation | A structured exercise, education and psychological programme, begun in hospital | Reduces mortality and readmission; one of the most effective and least delivered interventions |
Common mistakes
Watch outCalling a normal ECG reassuring in a patient with chest pain. The trace may be normal in the first hour of an infarction and in unstable angina, so the decision rests on the history and the troponin, not on the absence of ST elevation.
Watch outAttributing pleuritic or positional pain to a musculoskeletal cause without excluding the dangerous alternatives. Worse-on-breathing pain suggests pleurisy, but a pulmonary embolism and a pericarditis produce the same character, and a dissection produces a tearing pain that radiates to the back.
Watch outGiving nitrates to a hypotensive patient or to one with an inferior infarction and a raised jugular venous pressure, in whom a right ventricular infarction may be present. Nitrates reduce preload and can precipitate collapse in that setting.
Watch outTreating the troponin as a test for ischaemia. It is a test for myocardial necrosis, and it is raised in pulmonary embolism, myocarditis, sepsis, renal failure and heart failure — so a positive result must be interpreted with the ECG and the clinical picture.
Check your understanding
Why does a patient with stable angina have no pain at rest and pain on climbing stairs?
Which three items separate stable angina from an acute coronary syndrome in the history?
A patient has ST elevation in leads II, III and aVF with ST depression in I and aVL. Which territory and artery, and which electrocardiographic lead set should be added?
Multiple choice
A 58-year-old man has 40 minutes of central chest pain with sweating, and the ECG shows 3 millimetres of ST elevation in V2 to V5. What is the immediate priority?
Which pattern of ST elevation changes indicates an inferior myocardial infarction?
A patient presents with 30 minutes of chest pain at rest, an ECG with ST depression in the lateral leads, and a raised troponin. Which is the most likely diagnosis?
A patient is admitted with a non-ST-elevation acute coronary syndrome. Which drug is given immediately to every such patient unless contraindicated?
Which finding in a patient with an inferior infarction and a raised jugular venous pressure most changes the immediate management?
Module summary and next
Ischaemic heart disease is a demand-supply mismatch produced by atherosclerosis. Stable plaques narrow the artery and cause exertional angina; rupture converts a stable lesion into an occlusive thrombus, and the resulting acute coronary syndrome is classified by the ECG and the troponin. The therapeutic consequence is a division of labour: reperfusion for the occlusion, drugs for the demand, and aggressive secondary prevention for the disease that produced the plaque.
Next: arrhythmias and conduction disease — the electrical consequence of the infarction, ischaemia and scar that this lesson has described, and the group of disorders in which the ECG is the diagnosis.